Clinical Trials · NCT05407961
A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 90
- Start date
- Jun 2022
- Locations
- 1 site, Germany
- Primary endpoint
- Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration